Glenn P. Muir's Insider Trades & SAST Disclosures
Glenn P. Muir's most recent trade in Neuronetics Inc was a trade of 44,444 Common Stock done at an average price of $2.3 . Disclosure was reported to the exchange on Feb. 7, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Glenn P. Muir.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Neuronetics Inc | Glenn P. Muir | Director | Other type of transaction at price $ 2.25 per share. | 07 Feb 2025 | 44,444 | 334,262 (1%) | 0% | 2.3 | 99,999 | Common Stock |
| Repligen Corp. | Glenn P. Muir | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.29 per share. | 19 Nov 2024 | 19,000 | 32,283 (0%) | 0% | 36.3 | 689,510 | Common Stock |
| Repligen Corp. | Glenn P. Muir | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Nov 2024 | 19,000 | 0 | - | - | Stock Option (Right to Buy) | |
| G1 Therapeutics Inc | Glenn P. Muir | Director | 18 Sep 2024 | 185,358 | 0 (0%) | 0% | - | Common Stock | ||
| G1 Therapeutics Inc | Glenn P. Muir | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Sep 2024 | 50,000 | 0 | - | - | Stock Option (right to buy) | |
| G1 Therapeutics Inc | Glenn P. Muir | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Sep 2024 | 30,000 | 0 | - | - | Stock Option (right to buy) | |
| G1 Therapeutics Inc | Glenn P. Muir | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Sep 2024 | 30,000 | 0 | - | - | Stock Option (right to buy) | |
| G1 Therapeutics Inc | Glenn P. Muir | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Sep 2024 | 30,000 | 0 | - | - | Stock Option (right to buy) | |
| G1 Therapeutics Inc | Glenn P. Muir | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Sep 2024 | 20,000 | 185,358 (0%) | 0% | - | Common Stock | |
| Neuronetics Inc | Glenn P. Muir | Director | Purchase of securities on an exchange or from another person at price $ 0.80 per share. | 05 Sep 2024 | 25,000 | 289,818 (1%) | 0% | 0.8 | 20,000 | Common Stock |
| Neuronetics Inc | Glenn P. Muir | Director | Purchase of securities on an exchange or from another person at price $ 0.85 per share. | 28 Aug 2024 | 12,776 | 252,594 (1%) | 0% | 0.9 | 10,860 | Common Stock |
| Neuronetics Inc | Glenn P. Muir | Director | Purchase of securities on an exchange or from another person at price $ 0.85 per share. | 28 Aug 2024 | 12,224 | 264,818 (1%) | 0% | 0.8 | 10,390 | Common Stock |
| Neuronetics Inc | Glenn P. Muir | Director | Purchase of securities on an exchange or from another person at price $ 1.00 per share. | 20 Aug 2024 | 25,000 | 239,818 (1%) | 0% | 1 | 25,000 | Common Stock |
| Neuronetics Inc | Glenn P. Muir | Director | Purchase of securities on an exchange or from another person at price $ 0.75 per share. | 14 Aug 2024 | 25,171 | 214,818 (1%) | 0% | 0.7 | 18,878 | Common Stock |
| Repligen Corp. | Glenn P. Muir | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2024 | 5,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Repligen Corp. | Glenn P. Muir | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.29 per share. | 01 Aug 2024 | 5,000 | 13,283 (0%) | 0% | 36.3 | 181,450 | Common Stock |
| G1 Therapeutics Inc | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 30,000 | 30,000 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 10,000 | 205,358 (0%) | 0% | 0 | Common Stock | |
| Neuronetics Inc | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 25,000 | 189,647 (1%) | 0% | - | Common Stock | |
| Repligen Corp. | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 1,376 | 1,376 | - | - | Stock Option (Right to Buy) | |
| Repligen Corp. | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 701 | 8,283 (0%) | 0% | 0 | Common Stock | |
| G1 Therapeutics Inc | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 30,000 | 30,000 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 10,000 | 195,358 (0%) | 0% | 0 | Common Stock | |
| Neuronetics Inc | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 36,364 | 164,647 (0%) | 0% | - | Common Stock | |
| Repligen Corp. | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 1,487 | 1,487 | - | - | Stock Option (Right to Buy) | |
| Repligen Corp. | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 686 | 7,582 (0%) | 0% | 0 | Common Stock | |
| G1 Therapeutics Inc | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 30,000 | 30,000 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 10,000 | 185,358 (0%) | 0% | 0 | Common Stock | |
| Neuronetics Inc | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 38,910 | 128,271 (0%) | 0% | - | Common Stock | |
| Repligen Corp. | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 1,298 | 1,298 | - | - | Stock Option (Right to Buy) | |
| Repligen Corp. | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 534 | 6,896 (0%) | 0% | 0 | Common Stock | |
| G1 Therapeutics Inc | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 19,620 | 19,620 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 4,389 | 175,358 (0%) | 0% | 0 | Common Stock | |
| Neuronetics Inc | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 7,137 | 89,373 (0%) | 0% | - | Common Stock | |
| Repligen Corp. | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2021 | 1,151 | 1,151 | - | - | Stock Option (Right to Buy) | |
| Repligen Corp. | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2021 | 457 | 6,362 (0%) | 0% | 0 | Common Stock | |
| G1 Therapeutics Inc | Glenn P. Muir | Director | Purchase of securities on an exchange or from another person at price $ 13.50 per share. | 18 Nov 2020 | 50,000 | 170,969 (0%) | 0% | 13.5 | 675,000 | Common Stock |
| Neuronetics Inc | Glenn P. Muir | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2020 | 18,513 | 82,236 (0%) | 0% | - | Common Stock | |
| G1 Therapeutics Inc | Glenn P. Muir | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Neuronetics Inc | Glenn P. Muir | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2020 | 20,000 | 63,723 (0%) | 0% | - | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges